$83.44
0.60[0.72%]
At close: May 17
$83.44
0[0.00%]
After Hours: 4:07PM EDT
Bio-Techne
(NASDAQ:TECH)Bio-Techne Stock (NASDAQ:TECH), Analyst Ratings, Price Targets, Predictions
Bio-Techne Corp has a consensus price target of $134.29, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Benchmark, Baird, and Deutsche Bank on May 2, 2024, May 2, 2024, and April 18, 2024. With an average price target of $86 between Benchmark, Baird, and Deutsche Bank, there's an implied 3.07% upside for Bio-Techne Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
Baird
Deutsche Bank
Stifel
Stephens & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Bio-Techne
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/02/2024 | Buy Now | 13.85% | Benchmark | Robert Wasserman | → $95 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | -2.92% | Baird | Catherine Schulte | $73 → $81 | Maintains | Outperform | Get Alert |
| 04/18/2024 | Buy Now | -1.73% | Deutsche Bank | Justin Bowers | $85 → $82 | Maintains | Buy | Get Alert |
| 02/02/2024 | Buy Now | -22.1% | Stifel | Daniel Arias | → $65 | Downgrade | Buy → Hold | Get Alert |
| 02/02/2024 | Buy Now | 4.27% | Stephens & Co. | Jacob Johnson | $92 → $87 | Maintains | Overweight | Get Alert |
| 02/02/2024 | Buy Now | -10.12% | RBC Capital | Conor McNamara | $85 → $75 | Maintains | Sector Perform | Get Alert |
| 12/07/2023 | Buy Now | -4.12% | UBS | Dan Leonard | → $80 | Initiates | → Buy | Get Alert |
| 11/02/2023 | Buy Now | -22.1% | Stifel | Daniel Arias | $104 → $65 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | -4.12% | Citigroup | Patrick Donnelly | $100 → $80 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | -0.53% | RBC Capital | Conor McNamara | $85 → $83 | Maintains | Sector Perform | Get Alert |
| 11/01/2023 | Buy Now | -4.12% | Keybanc | Paul Knight | $115 → $80 | Maintains | Overweight | Get Alert |
| 09/12/2023 | Buy Now | 3.07% | RBC Capital | Conor McNamara | → $86 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/28/2023 | Buy Now | — | William Blair | Matt Larew | — | Initiates | → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 43.82% | Benchmark | Robert Wasserman | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 19.85% | Stephens & Co. | Jacob Johnson | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 7.86% | RBC Capital | Conor McNamara | $89 → $90 | Maintains | Sector Perform | Get Alert |
| 05/04/2023 | Buy Now | 19.85% | Stephens & Co. | Jacob Johnson | → $100 | Reiterates | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 19.85% | Baird | Catherine Schulte | $99 → $100 | Maintains | Outperform | Get Alert |
| 02/06/2023 | Buy Now | 5.47% | RBC Capital | Conor McNamara | $89 → $88 | Maintains | Sector Perform | Get Alert |
| 02/03/2023 | Buy Now | 43.82% | Benchmark | Robert Wasserman | → $120 | Maintains | Buy | Get Alert |
| 02/03/2023 | Buy Now | 31.83% | SVB Leerink | Puneet Souda | $125 → $110 | Maintains | Outperform | Get Alert |
| 02/03/2023 | Buy Now | 37.82% | Keybanc | Paul Knight | $125 → $115 | Maintains | Overweight | Get Alert |
| 01/10/2023 | Buy Now | 7.86% | Wells Fargo | Timothy Daley | → $90 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 12/14/2022 | Buy Now | 19.85% | Deutsche Bank | Justin Bowers | → $100 | Initiates | → Buy | Get Alert |
| 12/12/2022 | Buy Now | 19.85% | Citigroup | Patrick Donnelly | $81.25 → $100 | Upgrade | Neutral → Buy | Get Alert |
| 12/07/2022 | Buy Now | 6.66% | RBC Capital | Conor McNamara | → $89 | Initiates | → Sector Perform | Get Alert |
| 12/05/2022 | Buy Now | 25.84% | Stephens & Co. | Jacob Johnson | $420 → $105 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | 499.23% | SVB Leerink | Puneet Souda | $137.5 → $125 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | 457.29% | Credit Suisse | Dan Leonard | → $116.25 | Initiates | → Outperform | Get Alert |
| 08/16/2022 | Buy Now | 331.45% | Wells Fargo | Timothy Daley | $92.5 → $90 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for Bio-Techne (TECH)?
The latest price target for Bio-Techne (NASDAQ: TECH) was reported by Benchmark on May 2, 2024. The analyst firm set a price target for $95.00 expecting TECH to rise to within 12 months (a possible 13.85% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Techne (TECH)?
The latest analyst rating for Bio-Techne (NASDAQ: TECH) was provided by Benchmark, and Bio-Techne reiterated their buy rating.
When was the last upgrade for Bio-Techne (TECH)?
The last upgrade for Bio-Techne Corp happened on January 10, 2023 when Wells Fargo raised their price target to $90. Wells Fargo previously had an underweight for Bio-Techne Corp.
When was the last downgrade for Bio-Techne (TECH)?
The last downgrade for Bio-Techne Corp happened on February 2, 2024 when Stifel changed their price target from N/A to $65 for Bio-Techne Corp.
When is the next analyst rating going to be posted or updated for Bio-Techne (TECH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Techne, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Techne was filed on May 2, 2024 so you should expect the next rating to be made available sometime around May 2, 2025.
Is the Analyst Rating Bio-Techne (TECH) correct?
While ratings are subjective and will change, the latest Bio-Techne (TECH) rating was a reiterated with a price target of $0.00 to $95.00. The current price Bio-Techne (TECH) is trading at is $83.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.